Sign inCreate account

Report workspace tools

NCT06272227UNKNOWNanonymous

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial

Sponsor

Source record

Yonsei University

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Muscle function improvement in osteoporosis patients

Indication / condition

AI-normalized

Sarcopenia

Intervention

Source record

alfacalcidol, placebo, Denosumab

Source & freshness

Source record

NCT ID

NCT06272227

Original source

ClinicalTrials.gov

Source last updated

Feb 22, 2024

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06272227

Title

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial

Sponsor

Yonsei University

Status

UNKNOWN

Phase

PHASE4

Condition raw

Sarcopenia

Condition normalized

Sarcopenia

Modality raw

Sarcopenia

Modality normalized

monoclonal antibody

Target raw

Muscle function improvement in osteoporosis patients

Target normalized

Muscle function improvement in osteoporosis patients

Interventions

alfacalcidol, placebo, Denosumab

Public preview

Source record

This clinical trial, sponsored by Yonsei University, aims to evaluate the efficacy of alfacalcidol in enhancing muscle function in postmenopausal women with osteoporosis and functional sarcopenia. The study will involve 340 participants over a one-year period, comparing outcomes between the alfacalcidol and placebo groups.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06272227

Status

UNKNOWN

Phase

PHASE4

Sponsor

Yonsei University

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Yonsei University, aims to evaluate the efficacy of alfacalcidol in enhancing muscle function in postmenopausal women with osteoporosis and functional sarcopenia. The study will involve 340 participants over a one-year period, comparing outcomes between the alfacalcidol and placebo groups.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 22, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06272227

Indication

Sarcopenia

Modality

monoclonal antibody

Target

Muscle function improvement in osteoporosis patients

Intervention

alfacalcidol, placebo, Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.